---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-018214"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:39:12.892164+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Vistagen to present fasedienol and itruvone data at ASCP conference May 28-31

## Summary
- Poster on fasedienol (Phase 3 for social anxiety disorder) from PALISADE-2 trial on May 29.
- Poster on intranasal itruvone (Phase 2 for major depressive disorder) distribution in rats on May 29.
- Posters will be available on Vistagen website on June 3, 2024.

## SEC filing metadata
- accession: 0001437749-24-018214
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924018214/0001437749-24-018214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924018214/vtgn20240523_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-018214
- JSON: https://secwatch.observer/filing/0001437749-24-018214.json
- Plain text: https://secwatch.observer/filing/0001437749-24-018214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.